Focused ultrasound (FUS)-microbubble (MB) treatment transiently opens the blood brain barrier BBB), allowing enhanced drug delivery to brain. Previous studies have demonstrated that FUS-MB enhanced delivery of exogenous anti-amyloid-β antibodies in Alzheimer’s disease (AD) mouse models (Raymond et al., PLoS ONE 2008) and reduced plaque burden (Jordao et al., PLoS ONE 2010). Anti-amyloid immunotherapy clinical trials have reported transient vascular adverse events, such as vasogenic edema and microhemorrhage, especially in individuals with pre-existing vascular amyloid known as congophilic amyloid angiopathy (CAA). To our knowledge, it is currently unknown whether FUS-MB-mediated enhanced delivery of an anti-amyloid-β monoclonal antibody (mAb) in aged AD transgenic mice with both plaque and vascular amyloid deposition will be efficacious and/or whether enhancing antibody delivery to brain in the context of CAA may increase the incidence of microhemorrhage.
No reports found.